Lipigon Pharmaceuticals

Less than 1K followers

Overview

Investor consensus

All

Press releases

ShowingAll content types

Regulatory press release12/3/2025, 5:55 PM

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals

Press release11/21/2025, 11:19 AM

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals

Press release10/14/2025, 8:58 PM

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release8/26/2025, 12:28 PM

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals

Regulatory press release7/6/2025, 7:03 AM

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals

Press release5/27/2025, 6:36 AM

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals

Press release3/31/2025, 6:25 AM

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals

Regulatory press release3/20/2025, 11:15 AM

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals

Press release11/21/2024, 1:12 PM

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals

Regulatory press release11/21/2024, 9:00 AM

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals

Press release9/18/2024, 10:51 AM

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals

Press release8/28/2024, 5:43 AM

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals

Regulatory press release7/9/2024, 12:00 PM

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals

Press release6/20/2024, 6:30 AM

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals

Press release5/29/2024, 6:03 AM

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals

Press release5/15/2024, 6:28 AM

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals

Regulatory press release5/14/2024, 5:53 AM

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals

Press release2/23/2024, 7:08 AM

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals

Press release2/7/2024, 3:00 PM

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals

Press release12/12/2023, 9:11 AM

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.